Tracee Fultz is the Americas TP Controversy Leaderfor EYand practices in the area of intercompany pricing for Fortune 500 and Financial Times Stock Exchange (FTSE) 100 companies, specifically life science and technology companies. Tracee believes in the following principles of tax planning: a company’s business and corporate strategy will determine the appropriate tax planning, a company’s tax strategy should be practical enough to implement, sustain and govern, and a company should consider the tax life cycle of planning, compliance and controversy when planning. Tracee is active in numerous transfer pricing advisory projects including legislative reform, transactions, treasury planning and controversy defense. Most of the issues are related to intangible good transactions and business restructuring. Tracee received an MPA in Health Care Management and Policy from New York University focused on health care economics. She is a mathematician and health services researcher. Tracee previously worked as a manager of transfer pricing in Amgen’s tax department.
